Edition:
United States

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

3.06USD
4:00pm EDT
Change (% chg)

$-0.11 (-3.47%)
Prev Close
$3.17
Open
$3.19
Day's High
$3.21
Day's Low
$3.01
Volume
20,755
Avg. Vol
62,606
52-wk High
$4.04
52-wk Low
$1.80

Chart for

About

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged... (more)

Overall

Beta: 2.03
Market Cap(Mil.): $95.45
Shares Outstanding(Mil.): 30.11
Dividend: --
Yield (%): --

Financials

  SPHS.OQ Industry Sector
P/E (TTM): -- 29.26 33.20
EPS (TTM): -0.31 -- --
ROI: -41.67 13.66 13.23
ROE: -111.96 15.51 15.28

BRIEF-Sophiris Bio Reports Q1 Loss Per Share $0.11

* SOPHIRIS BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS

May 14 2018

BRIEF-Sophiris Bio Q4 Loss Per Share $0.13

* SOPHIRIS BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS

Mar 21 2018

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,794 +13.00
Pfizer Inc. (PFE.N) $37.38 -0.15
Merck & Co., Inc. (MRK.N) $62.59 -0.30
Sanofi SA (SASY.PA) €71.66 --
GlaxoSmithKline plc (GSK.L) 1,558.20 -17.80
Eli Lilly And Co (LLY.N) $89.07 -0.64

Earnings vs. Estimates